Recent evidence has shown that bevacizumab and aflibercept, anti-VEGF agents commonly used for treatment of retinal disorders associated with neovascularization including DR and AMD, have almost no toxic effect on RPE cells, ganglion cells, neuroretinal cells, and choroidal endothelial cells under normal conditions in vitro [91,93]. The gene discussed is VEGFA; the disease is retinal disorder.